CA2585490A1 - Composes heteroaromatiques de l'azote qui se lient au site actif d'enzymes de type proteines kinases - Google Patents
Composes heteroaromatiques de l'azote qui se lient au site actif d'enzymes de type proteines kinases Download PDFInfo
- Publication number
- CA2585490A1 CA2585490A1 CA002585490A CA2585490A CA2585490A1 CA 2585490 A1 CA2585490 A1 CA 2585490A1 CA 002585490 A CA002585490 A CA 002585490A CA 2585490 A CA2585490 A CA 2585490A CA 2585490 A1 CA2585490 A1 CA 2585490A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- alkoxy
- nr4r5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0425026.2 | 2004-11-12 | ||
GB0425026A GB0425026D0 (en) | 2004-11-12 | 2004-11-12 | Compounds which bind to the active site of protein kinase enzymes |
GB0500245.6 | 2005-01-07 | ||
GBGB0500245.6A GB0500245D0 (en) | 2004-11-12 | 2005-01-07 | Compounds which bind to the active site of protein kinase enzymes |
PCT/GB2005/004358 WO2006051311A1 (fr) | 2004-11-12 | 2005-11-11 | Composés hétéroaromatiques de l'azote qui se lient au site actif d'enzymes de type protéines kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2585490A1 true CA2585490A1 (fr) | 2006-05-18 |
Family
ID=35788166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002585490A Abandoned CA2585490A1 (fr) | 2004-11-12 | 2005-11-11 | Composes heteroaromatiques de l'azote qui se lient au site actif d'enzymes de type proteines kinases |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1814856A1 (fr) |
JP (1) | JP2008519814A (fr) |
CA (1) | CA2585490A1 (fr) |
WO (1) | WO2006051311A1 (fr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1922306A2 (fr) * | 2005-09-02 | 2008-05-21 | Astellas Pharma Inc. | Dérivés d'amides comme inhibiteurs rock |
WO2008022164A2 (fr) * | 2006-08-16 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Composés de pyrazine, leur utilisation et procédés de préparation |
US8071779B2 (en) * | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
BRPI0810202A2 (pt) | 2007-05-03 | 2014-10-21 | Pfizer Ltd | Derivados de piridina |
PL2190825T3 (pl) | 2007-08-22 | 2014-09-30 | Novartis Ag | Związki 5-(4-(chlorowcoalkoksy)-fenylo)-pirymidyno-2-aminowe i kompozycje jako inhibitory kinazy |
TWI504395B (zh) | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
TWI461197B (zh) | 2009-03-12 | 2014-11-21 | 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier | |
TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
TW201038565A (en) | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
ES2459468T3 (es) * | 2009-05-15 | 2014-05-09 | Novartis Ag | Arilpiridinas como inhibidores de aldosterona sintasa |
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
BR122019013687B1 (pt) * | 2009-06-12 | 2020-04-14 | Abivax | composto de fórmula (i) |
CN102822150B (zh) | 2010-02-05 | 2014-12-03 | 赫普泰雅治疗有限公司 | 1,2,4-三嗪-4-胺衍生物 |
JP5605727B2 (ja) * | 2010-04-06 | 2014-10-15 | Jnc株式会社 | セレンテラジン類縁体及びセレンテラミド類縁体 |
US8653101B2 (en) | 2010-08-27 | 2014-02-18 | Gruenenthal Gmbh | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators |
BR112013004690A2 (pt) | 2010-08-27 | 2016-05-10 | Gruenenthal Gmbh | 2-oxo-e 2-tioxo-di-hidroquinolina-3-carboxamidas substituídas como moduladores kcnq2/3 |
US8470852B2 (en) | 2010-08-27 | 2013-06-25 | Gruenenthal Gmbh | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators |
CA2807886A1 (fr) | 2010-09-01 | 2012-03-08 | Gruenenthal Gmbh | 1-oxo-dihydroisoquinoline-3-carboxamides substitues en tant que modulateurs des kcnq2/3 |
CA2816679A1 (fr) * | 2010-11-17 | 2012-05-24 | Novartis Ag | Composes 3-(aminoaryl)-pyridine |
US9458147B2 (en) | 2012-02-22 | 2016-10-04 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as TNAP inhibitors |
EP2757161A1 (fr) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 comme biomarqueur de l'infection virale |
KR102177199B1 (ko) | 2013-04-24 | 2020-11-10 | 고쿠리쓰다이가쿠호진 규슈다이가쿠 | 안저질환 치료제 |
MY182908A (en) | 2014-01-14 | 2021-02-05 | Millennium Pharm Inc | Heteroaryls and uses thereof |
EP3094326A4 (fr) | 2014-01-14 | 2017-07-26 | Millennium Pharmaceuticals, Inc. | Hétéroaryles et utilisations de ceux-ci |
EP2974729A1 (fr) | 2014-07-17 | 2016-01-20 | Abivax | Dérivés de quinoléine utilisés dans le traitement de maladies inflammatoires |
US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
SI3319959T1 (sl) | 2015-07-06 | 2022-02-28 | Alkermes, Inc. | Hetero-halo inhibitorji histonske deacetilaze |
EP4088719A1 (fr) | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Procédés et compositions pharmaceutiques pour le traitement de non-perfusion capillaire rétinienne |
US20180296474A1 (en) | 2015-10-13 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
JP6946412B2 (ja) | 2016-07-18 | 2021-10-06 | ヤンセン ファーマシューティカ エヌ.ベー. | タウpet画像化リガンド |
MD3570834T2 (ro) | 2017-01-11 | 2022-04-30 | Alkermes Inc | Inhibitori biciclici ai histon deacetilazei |
MA49839B1 (fr) | 2017-08-07 | 2022-05-31 | Alkermes Inc | Inhibiteurs bicycliques de la histone déacétylase |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
SG11202107615TA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
KR20220064369A (ko) | 2019-08-14 | 2022-05-18 | 인사이트 코포레이션 | Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물 |
CA3157681A1 (fr) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Amines bicycliques utilisees en tant qu'inhibiteurs de cdk2 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU779908B2 (en) * | 1999-09-10 | 2005-02-17 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
DE60136731D1 (de) * | 2000-09-20 | 2009-01-08 | Ortho Mcneil Pharm Inc | Pyrazine derivate als tyrosin kinase modulatoren |
GB2392154B (en) * | 2002-05-23 | 2005-01-19 | Cytopia Pty Ltd | Protein Kinase Inhibitors |
WO2005003101A2 (fr) * | 2003-07-02 | 2005-01-13 | Biofocus Discovery Limited | Composes se liant au site actif d'enzymes proteine kinases |
-
2005
- 2005-11-11 EP EP05809312A patent/EP1814856A1/fr not_active Withdrawn
- 2005-11-11 WO PCT/GB2005/004358 patent/WO2006051311A1/fr active Application Filing
- 2005-11-11 JP JP2007540715A patent/JP2008519814A/ja not_active Abandoned
- 2005-11-11 CA CA002585490A patent/CA2585490A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2008519814A (ja) | 2008-06-12 |
EP1814856A1 (fr) | 2007-08-08 |
WO2006051311A1 (fr) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2585490A1 (fr) | Composes heteroaromatiques de l'azote qui se lient au site actif d'enzymes de type proteines kinases | |
US20080194584A1 (en) | Nitrogen Heteroaromatic Compounds Which Bind To The Active Site Of Protein Kinase Enzymes | |
WO2005003101A2 (fr) | Composes se liant au site actif d'enzymes proteine kinases | |
TWI377198B (en) | Novel pyridine derivatives and pyrimidine derivatives (3) | |
TWI338684B (en) | Tetrahydroquinoline derivatives and a process for preparing the same | |
US20060199821A1 (en) | Heterocyclic amides and sulfonamides | |
TW201704237A (zh) | 適用於治療與kit及pdfgr相關之病症的組合物 | |
TW200526635A (en) | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity | |
KR20070026357A (ko) | 인돌 유도체, 및 키나제 억제제, 특히 ikk2억제제로서의 그의 용도 | |
KR20130109943A (ko) | 항암 및 항증식 활성을 나타내는 시클로프로필 디카르복사미드 및 유사체 | |
JP7195436B2 (ja) | バニン阻害剤としての複素芳香族化合物 | |
JP5412430B2 (ja) | mGlu5拮抗薬としての新規複素環系化合物 | |
WO2018121650A1 (fr) | Inhibiteur de fgfr | |
Hobson et al. | Identification of selective dual ROCK1 and ROCK2 inhibitors using structure-based drug design | |
CN111620878A (zh) | 吡咯并嘧啶类衍生物作为蛋白激酶抑制剂及其应用 | |
AU758246B2 (en) | N,N-substituted cyclic amine derivatives | |
WO2006072792A2 (fr) | Composes se liant au site actif des proteines kinases | |
SK6862003A3 (en) | Guanidine and amidine derivatives as factor XA inhibitors, process for the preparation thereof, pharmaceutical composition and use thereof | |
EP2733144B1 (fr) | Nouveau composé ayant une activité d'inhibition de parp | |
US20090163515A1 (en) | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | |
KR100791693B1 (ko) | 항혈전제 및 항응고제로서의 n-(헤테로시클릴)벤젠 또는피리딘 술폰아미드 | |
TW201619134A (zh) | 取代苯基化合物 | |
US11078161B2 (en) | Rock-inhibiting compound and uses thereof | |
AU2004218180B2 (en) | Novel aminopyridine derivatives as mGluR5 antagonists | |
WO2003082263A1 (fr) | Acides sulfamiques utilises comme inhibiteurs de proteines tyrosines phosphatases cytoplasmiques humaines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |